A Phase 3 interventional study of memantine in Open-Angle Glaucoma, sponsored by Allergan. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-11-04.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Glaucoma, Open-Angle by AbbVie — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · AbbVie.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 3rd largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 1999, is one of 12 in phase 3, and was the 1st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 58 studies in Glaucoma, Open-Angle by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 12 · Phase 4 14
First in 1999; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,119 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 164 across the 34 interventional studies, 419 across the 23 observational. Of the 54 that completed or were terminated, 42 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized double-masked clinical trial of memantine in patients with glaucoma
Inclusion Criteria:
Progression of glaucoma
No study locations are listed for this record.
The record gives a start of Mar 1999, a primary completion of Jan 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine